Manchester, United States
BioAI, founded in 2020, is at the cutting edge of integrating multimodal AI to advance precision medicine. Headquartered in the United States, the company’s slogan, "Transforming Precision Medicine with Multimodal AI," captures its core mission of leveraging machine learning to unravel the causal biology of diseases, develop digital biomarkers, and identify novel drug targets.
The company’s flagship product, the PredictX Platform, offers a sophisticated toolset for analyzing a variety of data sources including Digital Pathology, Multiomics, and Real-World Evidence. This platform helps construct predictive and prognostic models across numerous therapeutic areas by deploying advanced methodologies such as in-silico phenotype projection and integrated deep learning.
With a strong track record of forming strategic partnerships within the Pharma industry, BioAI continues to deliver innovative solutions to its global clientele. The company’s recent financial milestone was a $500.00K Seed Round investment on 05 April 2024, underscoring investor confidence in its technological and business propositions.
